Skip to main content
VCbacked
Log inGet Started

Endlyz Therapeutics

Boston, United States

Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias.

$17.3M raised
Apr 2026
Seed
BiotechnologyHealth CareTherapeutics

Top Investors

AbbVieOxford Science EnterprisesDementia Discovery FundMichael J. Fox FoundationCentre for Drug Design & Discovery (CD3)

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Endlyz Therapeutics

How much funding has Endlyz Therapeutics raised?
Endlyz Therapeutics has raised $17.3M in total funding. The most recent round was Seed. The last funding was announced in April 2026.
Who are Endlyz Therapeutics's investors?
Endlyz Therapeutics's investors include AbbVie, Oxford Science Enterprises, Dementia Discovery Fund, Michael J. Fox Foundation, Centre for Drug Design & Discovery (CD3).
Where is Endlyz Therapeutics headquartered?
Endlyz Therapeutics is headquartered in Boston, United States.
What does Endlyz Therapeutics do?
Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias.
What stage is Endlyz Therapeutics at?
Endlyz Therapeutics is at the Seed stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Endlyz Therapeutics — Funding & Investors." VCBacked, April 23, 2026, https://www.vcbacked.co/company/endlyz-therapeutics. Accessed July 4, 2026.
APA
VCBacked. (2026). Endlyz Therapeutics — Funding & Investors. Retrieved July 4, 2026, from https://www.vcbacked.co/company/endlyz-therapeutics
Wikipedia (cite web)
{{cite web |title=Endlyz Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/endlyz-therapeutics |website=VCBacked |access-date=July 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Rapport Therapeutics
Boston$250.0M
Allterum Therapeutics
Houston$1.0M
AlpalifeBio
Woburn$9.8M
Renaissance BioScience
Vancouver$599K
Epsilogen
London$16.3M
Advanced Microbiome Interventions
Amsterdam$300K